Belite Bio ADR receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Belite Bio Inc ADR (BLTE)
Belite Bio Inc ADR stock price live, this page displays NASDAQ BLTE stock exchange data. View the BLTE premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Belite Bio Inc ADR real time stock price chart below.
What Is the Belite Bio Inc ADR Stock Price Today?
The Belite Bio Inc ADR stock price today is 151.72.
What Is the Stock Symbol for Belite Bio Inc ADR?
The stock symbol for Belite Bio Inc ADR is "BLTE."
What Stock Exchange Does Belite Bio Inc ADR Trade On?
Belite Bio Inc ADR is listed and trades on the NASDAQ stock exchange.
Is Belite Bio Inc ADR a Good Stock to Buy?
Determining whether Belite Bio Inc ADR, or any stock, is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BLTE quote. (ISIN: US07782B1044)
What Is the Belite Bio Inc ADR Stock Price Today?
The Belite Bio Inc ADR stock price today is 151.72.
What Is the Stock Symbol for Belite Bio Inc ADR?
The stock symbol for Belite Bio Inc ADR is "BLTE."
What Stock Exchange Does Belite Bio Inc ADR Trade On?
Belite Bio Inc ADR is listed and trades on the NASDAQ stock exchange.
Is Belite Bio Inc ADR a Good Stock to Buy?
Determining whether Belite Bio Inc ADR, or any stock, is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BLTE quote. (ISIN: US07782B1044)
Fair Value
An estimate of a Belite Bio ADR's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
151.15
158.24
52 wk Range
62.18
200.00
BLTE is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Belite Bio ADR's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
151.15158.24
52 wk Range
62.18200.00
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
BLTE Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Belite Bio ADR's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
214.00
Upside
+41.05%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
Belite Bio ADR receives Investment Bank Analyst Rating Update- Investing.com
Pro
- Belite Bio ADR receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Belite Bio ADR receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
8 Buy
0 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 214.00
(+41.05% Upside)
Belite Bio Inc ADR Earnings Call Summary for Q2/2026
- Belite Bio posted Q2 2026 adjusted EPS of -$0.54, beating consensus estimate of -$0.7525 by 28.24%; shares fell 7.08% in regular trading.
- FDA accepted tinlarebant NDA with priority review; PDUFA date set for Feb. 12, 2027, with intensive agency interactions expected Dec 2026-Jan 2027.
- Cash position of $780M supports commercialization runway; R&D expenses rose 65.5% to $18.2M, SG&A jumped 157% to $16.7M year-over-year.
- Company plans Commercial Day in Sept 2026, pediatric study for ages 3-11 in London, and geographic atrophy trial interim analysis in Q1 2027.
- Japan PMDA filing under review with approval expected ~3 months post-FDA decision; European filing planned after U.S. approval if successful.
Last Updated: 13/08/2026, 22:18
Read Full TranscriptEarnings
Latest Release
Aug 13, 2026
EPS / Forecast
-0.70 / -0.75
Revenue / Forecast
-- / --
Compare BLTE to Peers and Sector
Metrics to compare | BLTE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBLTEPeersSector | |
|---|---|---|---|---|
P/E Ratio | −59.7x | −11.8x | −0.4x | |
PEG Ratio | 0.79 | −0.26 | 0.00 | |
Price/Book | 7.9x | 1.1x | 2.6x | |
Price / LTM Sales | - | 2.4x | 3.1x | |
Upside (Analyst Target) | 38.4% | 129.0% | 47.7% | |
Fair Value Upside | Unlock | 5.8% | 6.5% | Unlock |
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Belite Bio ADR (BLTE) Stock Price Today?
The Belite Bio ADR stock price today is 151.72 USD.
What Stock Exchange Does Belite Bio ADR Trade On?
Belite Bio ADR is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Belite Bio ADR?
The stock symbol for Belite Bio ADR is "BLTE."
What Is the Belite Bio ADR Market Cap?
As of today, Belite Bio ADR market cap is 6.11B USD.
What Is Belite Bio ADR's Earnings Per Share (TTM)?
The Belite Bio ADR EPS (TTM) is -2.74.
When Is the Next Belite Bio ADR Earnings Date?
Belite Bio ADR will release its next earnings report on Nov 17, 2026.
From a Technical Analysis Perspective, Is BLTE a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Belite Bio ADR Stock Split?
Belite Bio ADR has split 0 times.
How Many Employees Does Belite Bio ADR Have?
Belite Bio ADR has 41 employees.
What is the current trading status of Belite Bio ADR (BLTE)?
As of Aug 31, 2026, Belite Bio ADR (BLTE) is trading at a price of 151.72 USD, with a previous close of 151.72 USD. The stock has fluctuated within a day range of 151.15 USD to 158.24 USD, while its 52-week range spans from 62.18 USD to 200.00 USD.
What Is Belite Bio ADR (BLTE) Price Target According to Analysts?
The average 12-month price target for Belite Bio ADR is 214.00 USD, with a high estimate of 270 USD and a low estimate of 185 USD. 8 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +41.05% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.